Meropenem Steriscience

What Is Meropenem Steriscience and What Is It Used For?

Meropenem Steriscience is a carbapenem-class antibiotic that kills bacteria by preventing them from forming protective cell walls. It is administered intravenously in hospitals to treat life-threatening infections including pneumonia, meningitis, intra-abdominal infections, complicated urinary tract infections, and sepsis.

Meropenem belongs to the carbapenem class of beta-lactam antibiotics, which are among the most potent and broad-spectrum antibiotics available in clinical medicine. Carbapenems are frequently considered "last-resort" antibiotics because they remain effective against many bacteria that have developed resistance to other antibiotic classes, including penicillins, cephalosporins, and fluoroquinolones. Meropenem Steriscience contains the active substance meropenem (as the trihydrate), supplied as a sterile powder that is reconstituted with a suitable diluent before intravenous administration.

The drug works by penetrating bacterial cells and binding to specific proteins called penicillin-binding proteins (PBPs), which are essential enzymes involved in synthesising the peptidoglycan layer of the bacterial cell wall. When meropenem inhibits these PBPs, the bacterium can no longer maintain its structural integrity and undergoes lysis (cell death). Unlike many older beta-lactam antibiotics, meropenem is highly resistant to degradation by beta-lactamase enzymes, including extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases, which are common mechanisms of bacterial resistance. However, meropenem can be hydrolysed by metallo-beta-lactamases and certain carbapenemases (such as KPC enzymes), which is a growing concern in antimicrobial resistance.

Meropenem Steriscience has a broad spectrum of activity encompassing many clinically important pathogens. It is effective against Gram-positive bacteria such as Streptococcus pneumoniae, Streptococcus pyogenes, and methicillin-susceptible Staphylococcus aureus (MSSA), although it is not active against methicillin-resistant Staphylococcus aureus (MRSA). Among Gram-negative organisms, meropenem covers Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Neisseria meningitidis, and many species of Enterobacter, Citrobacter, and Serratia. It is also active against many anaerobic bacteria including Bacteroides fragilis.

Approved indications

Meropenem Steriscience is approved for the treatment of the following infections in adults and children aged 3 months and older:

• Pneumonia including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)
• Complicated urinary tract infections including pyelonephritis
• Complicated intra-abdominal infections such as peritonitis, intra-abdominal abscess, and biliary tract infections
• Complicated skin and soft tissue infections including necrotising fasciitis and diabetic foot infections
• Acute bacterial meningitis
• Intra- and post-partum infections such as endometritis and puerperal sepsis
• Empirical therapy for febrile neutropenic patients suspected of having a bacterial infection
• Bacteraemia/sepsis that occurs in association with any of the above indications

What Should You Know Before Taking Meropenem Steriscience?

Before receiving meropenem, inform your doctor if you are allergic to any antibiotic (especially penicillins or cephalosporins), have kidney disease, liver problems, a history of seizures, or are pregnant or breastfeeding. Meropenem critically reduces valproic acid levels and should not be combined without careful monitoring.

Although meropenem is generally well tolerated, there are important safety considerations that must be evaluated before treatment is initiated. Your healthcare team will assess your medical history, current medications, and overall health status to ensure meropenem is appropriate for you. The following sections outline the key contraindications, warnings, and precautions associated with Meropenem Steriscience.

Contraindications

You should not receive Meropenem Steriscience if you have a known hypersensitivity (allergy) to meropenem, any other carbapenem antibiotic, or to any of the excipients in the formulation. Patients with a history of severe allergic reactions (such as anaphylaxis or severe skin reactions) to any beta-lactam antibiotic, including penicillins and cephalosporins, should be treated with extreme caution due to the possibility of cross-reactivity, although the incidence of cross-allergy between carbapenems and penicillins is relatively low (estimated at 1-3%).

Warnings and precautions

Special care is needed in the following situations:

• History of seizures or CNS disorders: Seizures and other central nervous system (CNS) adverse events have been reported with meropenem, particularly in patients with pre-existing CNS disorders (e.g., brain lesions, history of seizures) or impaired renal function where drug accumulation may occur. If seizures occur during treatment, the dose should be reviewed and anticonvulsant therapy may be necessary.
• Renal impairment: Meropenem is primarily eliminated by the kidneys. Patients with creatinine clearance below 51 mL/min require dose reduction to prevent accumulation of the drug and its metabolites, which increases the risk of adverse effects including seizures.
• Hepatic disease: Patients with pre-existing liver disease should be monitored with regular liver function tests during meropenem therapy, as transient elevations in hepatic enzymes and bilirubin have been observed.
• Clostridioides difficile-associated diarrhoea (CDAD): As with virtually all antibiotics, meropenem can cause antibiotic-associated colitis, ranging from mild diarrhoea to life-threatening pseudomembranous colitis caused by toxin-producing Clostridioides difficile. If significant diarrhoea develops during or after treatment, CDAD should be considered and treated appropriately.
• Superinfection: Prolonged use of meropenem may result in overgrowth of non-susceptible organisms, including fungi. Patients should be monitored for signs of superinfection.

Pregnancy and breastfeeding

The safety of meropenem during pregnancy has not been established in adequate human studies. Animal reproduction studies have not demonstrated evidence of teratogenicity or harm to fertility, but these findings cannot always be directly extrapolated to humans. Meropenem should only be used during pregnancy when the potential benefit to the mother clearly justifies the potential risk to the fetus. The decision to use meropenem in a pregnant patient should be made by a specialist, weighing the severity of the infection against the risks of untreated maternal infection.

Meropenem is excreted in human breast milk in small quantities. The effects on breastfed infants are unknown, but potential risks include disruption of the infant's intestinal flora, resulting in diarrhoea or fungal colonisation. A decision must be made whether to discontinue breastfeeding or to discontinue/refrain from meropenem therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.

How Does Meropenem Steriscience Interact with Other Drugs?

The most critical drug interaction is with valproic acid (Depakote, Epilim): meropenem can reduce valproic acid blood levels by 60-100%, leading to seizure breakthrough. Probenecid increases meropenem levels and is not recommended. Meropenem may also interact with warfarin and oral contraceptives.

Drug interactions can alter the effectiveness or safety of medications. While meropenem has relatively few clinically significant drug interactions compared to some other antibiotic classes, several important interactions must be considered. Always inform your healthcare team about all medications, supplements, and herbal products you are taking.

Major interactions

The interaction between meropenem and valproic acid (valproate, divalproex sodium) is the most clinically significant. Meropenem, like all carbapenem antibiotics, dramatically reduces serum valproic acid concentrations, typically by 60-100%. This reduction occurs rapidly, often within 24 hours of starting meropenem, and can persist for several days after the carbapenem is discontinued. The mechanism is not fully understood but is thought to involve increased hepatic glucuronidation of valproic acid and inhibition of its intestinal reabsorption. Importantly, this interaction cannot be overcome by increasing the valproic acid dose. Patients who depend on valproic acid for seizure control and require carbapenem therapy should be switched to an alternative antiepileptic drug, or an alternative antibiotic should be considered.

Minor interactions

Probenecid competes with meropenem for active renal tubular secretion, which can increase meropenem's plasma concentration and prolong its half-life. Since the pharmacokinetic profile of meropenem without probenecid is satisfactory, co-administration is not recommended. The interaction with warfarin and other oral anticoagulants is a class effect of many antibiotics; meropenem may potentiate the anticoagulant effect by reducing vitamin K-producing gut bacteria. Patients receiving concomitant anticoagulation should have their International Normalised Ratio (INR) monitored frequently during and shortly after meropenem therapy.

What Is the Correct Dosage of Meropenem Steriscience?

The standard adult dose of meropenem is 500 mg to 2 g given intravenously every 8 hours, depending on the type and severity of infection. Children aged 3 months and older receive 10-40 mg/kg every 8 hours. Dose reduction is essential in patients with kidney impairment (creatinine clearance below 51 mL/min).

Meropenem is exclusively administered by the intravenous route, either as a bolus injection over approximately 5 minutes or as an intravenous infusion over 15 to 30 minutes. The drug is supplied as a powder that must be reconstituted with a suitable diluent (such as water for injections or 0.9% sodium chloride) before administration. The dose, frequency, and duration of treatment depend on the type and severity of the infection, the susceptibility of the causative organism, and the patient's renal function.

Adults

Children (3 months and older)

For children aged 3 months to 11 years, the recommended dose of meropenem is based on body weight. The dosing is as follows:

Elderly

No dose adjustment is required solely on the basis of age in elderly patients with normal renal function. However, since renal function frequently declines with age, creatinine clearance should be estimated and dose adjustments made accordingly. Elderly patients should be monitored carefully for signs of adverse effects, particularly neurological symptoms such as confusion or seizures, which may indicate drug accumulation.

Renal impairment

Dose adjustment is essential in patients with impaired kidney function. The following guidelines apply for adults based on creatinine clearance (CrCl):

Meropenem is cleared by haemodialysis. If continued meropenem treatment is necessary, a supplementary dose (based on the infection type and severity) is recommended after each dialysis session to restore therapeutic plasma levels.

Missed dose

Since meropenem is administered in a hospital setting by healthcare professionals, the risk of a missed dose is minimised. If a dose is inadvertently missed, it should be given as soon as possible and the regular dosing schedule should then be resumed. The dose should not be doubled to make up for a missed dose.

Overdose

Accidental overdose is unlikely in the hospital setting but may occur, particularly in patients with renal impairment where drug accumulation can occur. Symptoms of overdose may include nausea, vomiting, diarrhoea, and neurological symptoms such as seizures, confusion, or altered consciousness. Treatment is supportive and symptomatic. Meropenem and its metabolite are removable by haemodialysis, which should be considered in severe overdose cases, particularly in patients with renal failure.

What Are the Side Effects of Meropenem Steriscience?

Common side effects include diarrhea, nausea, vomiting, injection site reactions (inflammation, pain), skin rash, and transient elevations in liver enzymes. Uncommon but important effects include oral and vaginal thrush, headache, and changes in blood counts. Rare but serious reactions include seizures, anaphylaxis, Stevens-Johnson syndrome, and Clostridioides difficile colitis.

Like all medicines, Meropenem Steriscience can cause side effects, although not everybody gets them. Most side effects are mild to moderate in severity and resolve after treatment is discontinued. However, some adverse reactions can be serious and require immediate medical attention. The following frequency-based classification is used in accordance with international regulatory standards (MedDRA convention).

Clinical trial data and extensive post-marketing surveillance have established that meropenem is generally well tolerated in both adults and children. The incidence of serious adverse reactions is low. However, as with all beta-lactam antibiotics, the risk of allergic reactions exists. Patients with a history of allergy to penicillins or cephalosporins have a slightly increased risk of allergic reactions to meropenem, although true cross-reactivity is uncommon. The risk of seizures is increased in patients with pre-existing CNS disorders, renal impairment (due to drug accumulation), or when recommended doses are exceeded.

Long-term or repeated use of meropenem can lead to superinfection with resistant organisms or fungi. Healthcare teams monitor patients for signs of emerging resistance and fungal overgrowth, particularly in critically ill patients on prolonged courses. If you experience any new or worsening symptoms during treatment, inform your healthcare team promptly.

How Should You Store Meropenem Steriscience?

Store unopened vials below 30°C. Do not freeze. After reconstitution, the solution should be used immediately or within 3 hours if kept at room temperature, or within 12 hours if refrigerated at 2-8°C. The reconstituted solution should not be frozen.

Proper storage of Meropenem Steriscience is essential to maintain the drug's potency and safety. Since this medicine is used in hospital settings, storage is managed by the pharmacy department, but the following general guidelines apply:

• Unopened vials: Store below 30°C in the original packaging to protect from light. Do not freeze.
• After reconstitution with water for injections: Solutions reconstituted with water for injections are chemically and physically stable for up to 3 hours at room temperature (up to 25°C) or up to 12 hours when stored in a refrigerator (2-8°C).
• After dilution in infusion bags: When diluted in 0.9% sodium chloride, the solution should be used within the same stability period as reconstituted solutions. Stability data vary depending on the diluent used; always follow the product's approved instructions.
• Do not use if the reconstituted solution appears discoloured, contains visible particles, or if the vial seal appears damaged.
• Keep out of the sight and reach of children.
• Do not use after the expiry date printed on the vial and carton.

What Does Meropenem Steriscience Contain?

Each vial of Meropenem Steriscience contains 1 g of meropenem (as meropenem trihydrate) as the active ingredient. The only excipient is anhydrous sodium carbonate (Na2CO3), which serves as a pH adjuster to create an alkaline environment for reconstitution.

Meropenem Steriscience is a relatively simple pharmaceutical formulation. The product contains:

• Active substance: Meropenem 1 g (as meropenem trihydrate, equivalent to 1,140 mg of meropenem trihydrate)
• Excipient: Anhydrous sodium carbonate (approximately 208 mg of sodium per 1 g vial)

The anhydrous sodium carbonate functions as a buffering agent, adjusting the pH of the reconstituted solution to an appropriate range for intravenous administration (approximately pH 7.3-8.3). The sodium content (approximately 208 mg, or 9.0 mmol per 1 g vial) should be taken into consideration for patients on a controlled sodium diet, particularly those with heart failure, renal impairment, or other conditions requiring sodium restriction.

The powder is a white to pale yellow crystalline powder. After reconstitution with water for injections, the solution should be clear and colourless to pale yellow. The vials are single-use; any unused solution should be discarded. Meropenem Steriscience does not contain any preservatives, latex, or gluten.

Physical appearance

Meropenem Steriscience 1 g is supplied as a sterile white to pale yellow powder in clear glass vials (Type I glass) with bromobutyl rubber stoppers and aluminium seals with plastic flip-off caps. Each vial is intended for single use only. The vials are available in pack sizes of 1, 10, or 20 vials, although not all pack sizes may be marketed in every country.